Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 19/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HK1 | P19367 | 1/20 | 0.43 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | PTGIR | P43119 | 1/20 | 0.42 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1466186 | 0.91 | PTGDR2 (0.64) | PTGDR2PTGIRPTGDR | |
| SCHEMBL1467834 | 0.90 | PTGDR2 (0.60) | PTGDR2ALDH1A1LMNAMAPTHK1 | |
| SCHEMBL1466489 | 0.89 | PTGDR2 (0.53) | PTGDR2ALDH1A1LMNAMAPTHK1 | |
| SCHEMBL3716596 | 0.84 | PTGDR2 (0.49) | PTGDR2ALDH1A1LMNAMAPTHK1 | |
| SCHEMBL1421903 | 0.84 | PTGDR2 (0.51) | PTGDR2ALDH1A1LMNAMAPTHK1 | |
| SCHEMBL1921378 | 0.82 | PTGDR2 (0.51) | PTGDR2ALDH1A1LMNAMAPTHK1 | |
| SCHEMBL3714601 | 0.82 | PTGDR2 (0.52) | PTGDR2ALDH1A1LMNAMAPTHK1 | |
| SCHEMBL1467495 | 0.81 | PTGDR2 (0.50) | PTGDR2ALDH1A1LMNAMAPTHK1 | |
| SCHEMBL1466111 | 0.81 | PTGDR2 (0.71) | PTGDR2PTGIRPTGDR | |
| SCHEMBL3718517 | 0.81 | PTGDR2 (0.48) | PTGDR2ALDH1A1LMNAMAPTHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130225617-A1 | INDOLES AND THEIR THERAPEUTIC USE | PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) | 2013-08-29 | — | — | US | disclosed |
| US-8394836-B2 | Indoles and their therapeutic use | PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) | 2013-03-12 | — | — | US | disclosed |
| EP-2327693-B9 | Indoles and their therapeutic use | PULMAGEN THERAPEUTICS ASTHMA LTD (GB) | 2012-10-24 | — | — | EP | disclosed |
| EP-2327693-B1 | Indoles and their therapeutic use | PULMAGEN THERAPEUTICS ASTHMA LTD (GB) | 2012-06-20 | — | — | EP | disclosed |
| EP-2327693-A1 | Indoles and their therapeutic use | Pulmagen Therapeutics (Asthma) Limited (GB) | 2011-06-01 | — | — | EP | disclosed |
| US-20110071175-A1 | Indoles and Their Therapeutic Use | GB005, INC. | 2011-03-24 | — | — | US | disclosed |
| EP-2229358-A1 | INDOLES AND THEIR THERAPEUTIC USE | Pulmagen Therapeutics (Asthma) Limited (GB) | 2010-09-22 | — | — | EP | disclosed |
| WO-2009077728-A1 | INDOLES AND THEIR THERAPEUTIC USE | ARGENTA DISCOVERY LIMITED (GB) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225617-A1 | INDOLES AND THEIR THERAPEUTIC USE | IDO2, IDO1, RORB | PTGDR2 39/4885ALDH1A1 1047/4885LMNA 4560/4885 |
| US-20110071175-A1 | Indoles and Their Therapeutic Use | FPR3, HRH2, HRH4 | PTGDR2 161/4885ALDH1A1 1510/4885LMNA 4764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.